IPOpulse
Back to Ticker

Onesource Specialty Pharma Limited

NSE: ONESOURCE
Healthcare Healthcare
₹1,366.6
-2.93%EOD · 19 Oct

Onesource Specialty Pharma Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap
₹15,671 Cr
52W Range
₹1925 / ₹1057
Volume
92K
44.7% delivery
1Y Return
-26.9%
P/B Ratio
2.8
ROE
-1.3%
Debt / Equity
25.79

Peers in Healthcare

Top 8 by market cap
CompanyLTP30DMarket CapP/EP/BROE %Div Yld %
Onesource Specialty Pharma Limited(this stock)₹1,366.6₹15,671 Cr—2.8-1.3%0.00%
Divi's Laboratories LimitedDIVISLAB₹9,087₹2.41 L Cr83.014.516.2%0.33%
Torrent Pharmaceuticals LimitedTORNTPHARM₹4,558.7₹1.73 L Cr72.818.417.0%0.83%
Laurus Labs LimitedLAURUSLABS₹2,069₹1.12 L Cr101.821.017.7%0.12%
Zydus Lifesciences LimitedZYDUSLIFE₹1,113.9₹1.11 L Cr25.04.218.3%0.09%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP₹7,700₹1.11 L Cr54.312.021.5%0.25%
Aurobindo Pharma LimitedAUROPHARMA₹1,621.4₹93,292 Cr26.12.69.9%0.00%
Mankind Pharma LimitedMANKIND₹2,253.2₹93,067 Cr46.05.812.4%0.00%
Max Healthcare Institute LimitedMAXHEALTH₹830₹80,785 Cr56.77.714.3%0.23%

Quality Score

Durability · Valuation · Momentum — objective math, not advice
D
27/100
Composite score: 40% quality, 30% valuation, 30% momentum
QualityPoor · 20
ValuationGood · 58
MomentumPoor · 5
Negative ROE
High debt load (D/E 25.8)
In confirmed downtrend (Stage 4)

Technical Indicators

Full analysis · objective math, not advice
Returns
1D
-2.9%
1W
-7.1%
1M
-13.5%
3M
-19.3%
6M
-11.5%
1Y
-26.9%
Weinstein Stage
Stage 4 — Declining (downtrend)
RSI (14)
21 Oversold
Trend Template
1/7weak
RS vs Nifty (3M)
-12.7pp
Moving Averages (price vs MA)
20-DMA
₹1512
below
50-DMA
₹1536
below
150-DMA
₹1606
below
200-DMA
₹1566
below
From 52W High
-29.0%
From 52W Low
+29.3%
Support (20D)
₹1352
Resistance (20D)
₹1643

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Community discussion(0)

Sign in to join the discussion.

Sign in

No comments yet — be the first to share your view.